Correction from 01/20/06 News Brief

Share this article:
An article appearing in January’s MM&M magazine, entitled “Fame and Pharma,” featured artwork of a spoof Bob Dole ad for Pfizer’s Viagra, along with a caption referencing this image. The use of this image and caption instead of the intended portrait photo of Sen. Dole was an error, which unfortunately was not spotted before the page went to press.  The article also referred to Sen. Dole’s Viagra campaign as “playful.”  This, too, was an error. MM&M acknowledges that the Viagra campaign was in fact a serious unbranded effort to promote awareness of erectile dysfunction. MM&M regrets these unfortunate errors and apologizes for any offense or embarrassment caused to Pfizer, its partners and to Sen. Dole.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...